Neutral
₹5,302
₹5,110
₹5,890
11.09%
In its November 12, 2026 results update, Motilal Oswal retained its Neutral rating on Alkem Laboratories. The broker expects FY27 to be a consolidation year, as new businesses face a gestation period, operating costs are front-loaded and revenues have yet to scale up. Regulatory issues at the Daman facility continue to weigh on financial performance and new ANDA approvals.
Motilal Oswal expects earnings growth to revive in FY28E as the biotech and med-tech businesses scale up and the India operations gain operating leverage.
Alkem reported 2QFY27 revenue of Rs 4,552 crore, up 13.8 per cent YoY and broadly in line with expectations. Revenue and EBITDA were marginally ahead of Motilal Oswal's estimates by around 4 per cent and 3 per cent, respectively, supported by better international performance, principally outside the US.
| Metric | 2QFY27 | YoY change |
|---|---|---|
| Revenue | Rs 4,552 crore | 13.8% increase |
| Gross margin | 67.2% | 220 bps expansion |
| EBITDA | Rs 1,025 crore | 11.3% increase |
| EBITDA margin | 22.5% | 50 bps decline |
| Adjusted PAT | Rs 652 crore | 14.8% decline |
Higher employee costs and R&D expenditure offset the benefit from the improved mix, resulting in a 50-basis-point YoY decline in EBITDA margin to 22.5 per cent. Adjusted PAT fell 14.8 per cent YoY to Rs 652 crore, broadly in line with estimates, owing to higher depreciation and tax. The result included a Rs 35 crore exceptional recovery against an impaired investment.
In 1HFY27, revenue and EBITDA rose 12 per cent and 8 per cent YoY to Rs 8,290 crore and Rs 1,790 crore, respectively, while PAT declined 17 per cent YoY to Rs 1,170 crore.
Domestic formulations revenue grew 9.5 per cent YoY to Rs 3,028 crore, representing 67 per cent of sales. Alkem outperformed the industry in chronic therapies, although mid-single-digit trade-generics growth was constrained by intensifying competition and tighter credit policies.
International revenue rose 22.3 per cent YoY to Rs 1,451 crore. US generics sales increased 2.4 per cent YoY to Rs 783 crore despite robust volume growth, as stronger price erosion and the gradual scale-up of products including g-tolvaptan affected sales. Other international sales rose 58.2 per cent YoY to Rs 671 crore, driven by execution in Latin America and delivering Alkem's highest quarterly non-US sales.
Management guided for around 11 per cent India-business growth in FY27, mid-single-digit US revenue growth in constant currency, and mid-to-high-teen non-US growth in FY27. Non-US growth is expected to sustain at mid-teens in FY28.
New businesses remain an important source of potential growth as well as near-term dilution. Core pharma EBITDA margin was about 26 per cent in 2QFY27, while Occlutech caused around 80 basis points of dilution.
Management expects Enzene revenue to double over four years and reach EBITDA breakeven in two years. The business requires incremental capex of Rs 300 crore to Rs 350 crore over three to four years. Enzene has been affected by the denosumab BLA setback, a slower US CDMO ramp-up and higher B2B biosimilar price erosion.
Med-tech revenue is expected to grow three times over five to six years and reach EBITDA breakeven in one year. Incremental capex of Rs 400 crore is expected over three to four years.
Motilal Oswal largely maintained its FY27E and FY28E estimates.
| Metric | FY27E | FY28E |
|---|---|---|
| Revenue | Rs 16,560 crore | Rs 18,290 crore |
| EBITDA | Rs 3,430 crore | Rs 4,060 crore |
| Adjusted PAT | Rs 2,229 crore | Rs 2,612 crore |
The broker forecasts international-market sales CAGR of 11.8 per cent to Rs 5,850 crore over FY26 to FY28. It values Alkem at 27 times 12-month forward earnings to derive a target price of Rs 5,890.
Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.
Copyright 2026 by DSIJ Wealth Advisory Pvt. Ltd. (Formerly Known as DSIJ Pvt. Ltd.)